Related Experiment Videos
Drug resistance mutations in HIV-1
Victoria A Johnson1, Françoise Brun-Vézinet, Bonaventura Clotet
1Veterans Affairs Medical Center, and University of Alabama School of Medicine, Birmingham, AL, USA.
Summary
The International AIDS Society-USA (IAS-USA) expert panel identifies human immunodeficiency virus type 1 (HIV-1) drug resistance mutations. They analyze data to pinpoint mutations linked to clinical resistance in patients receiving antiretroviral therapy.
Area of Science:
- Virology
- Infectious Diseases
- Molecular Biology
Background:
- The International AIDS Society-USA (IAS-USA) convenes an expert panel focused on HIV-1 drug resistance.
- Understanding resistance mutations is crucial for effective antiretroviral therapy (ART).
Purpose of the Study:
- To identify and interpret new data on HIV-1 drug resistance mutations.
- To pinpoint mutations associated with clinical resistance to antiretroviral drugs.
Main Methods:
- Expert panel review of new data on HIV-1 resistance.
- Identification of mutations through in vitro experiments, susceptibility testing, genetic sequencing, and correlation studies.
- Inclusion of drugs approved by the US Food and Drug Administration (FDA) or available via expanded access.
Main Results:
- The group identifies specific mutations linked to clinical resistance in HIV-1.
- Data is gathered from various sources including laboratory studies and patient clinical data.
Conclusions:
- The IAS-USA Drug Resistance Mutations Group provides critical insights into HIV-1 drug resistance.
- This work supports the optimization of treatment strategies for individuals with HIV-1.